menu
    • menu
    [{"orgOrder":0,"company":"Alcami","sponsor":"Trevena","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Oliceridine","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Alcami","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alcami \/ Trevena","highestDevelopmentStatusID":"12","companyTruncated":"Alcami \/ Trevena"},{"orgOrder":0,"company":"Alcami","sponsor":"PharmaTher","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alcami","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alcami \/ Alcami Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Alcami \/ Alcami Corporation"}]

    Find Clinical Drug Pipeline Developments & Deals by Alcami

    Menu

    Alcami

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alcami

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Alcami

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Recipient : PharmaTher

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products

                            Details : PharmaTher is evolving to become a leader in ketamine-based solutions for mental health, neurological and pain disorders, and partnering with Alcami as our exclusive manufacturer for the clinical and commercial supply of ketamine.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 19, 2021

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : PharmaTher

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alcami

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Alcami

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oliceridine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Trevena

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Alcami Providing Commercial Manufacturing for Trevena’s Recently FDA Approved OLINVYK

                            Details : Alcami is providing commercial manufacturing services for Trevena's newly approved OLINVYK. OLINVYK (oliceridine) injection is an opioid approved in adults for the management of acute pain severe enough to require an intravenous opioid analgesic.

                            Brand Name : Olinvyk

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 26, 2020

                            Lead Product(s) : Oliceridine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Trevena

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth